Kathryn Mileham, MD
Medical Oncology · Charlotte, NCNPI 1568519411
Payments from drug & device makers
Across 416 payments — averaging $11,384 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2.7M
- Merck$1.7M
- Bayer$74K
- Takeda Pharmaceuticals U.S.A., Inc.$63K
- Eli Lilly$58K
- AstraZeneca$38K
- plus $92K from 14 others
Across 2 payments — averaging $2878.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$5K
- Eli Lilly$594
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $2,667,772 |
| Merck | 312 | $1,742,990 |
| Bayer | 8 | $73,614 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $62,826 |
| Eli Lilly | 4 | $58,014 |
| AstraZeneca | 33 | $38,155 |
| Boehringer Ingelheim International GmbH | 13 | $35,685 |
| Bristol Myers Squibb | 2 | $13,942 |
| Genentech, Inc. | 1 | $12,000 |
| Novartis | 1 | $7,090 |
| Lilly USA, LLC | 2 | $5,714 |
| Blueprint Medicines Corporation | 2 | $5,141 |
| Regeneron Healthcare Solutions, Inc. | 4 | $4,061 |
| AbbVie | 1 | $2,900 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,970 |
| Johnson & Johnson | 2 | $1,810 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Genentech USA, Inc. | 1 | $550 |
| Jazz Pharmaceuticals Inc. | 1 | $62 |
| Janssen Scientific Affairs, LLC | 1 | $45 |
How this compares
$4,735,842 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Charlotte
- Antoinette TanCharlotte$14.9M
- Nilanjan GhoshCharlotte$6.3M
- David RizzieriCharlotte$1.8M
- Edward KimCharlotte$1.7M
- Jimmy HwangCharlotte$1.3M
- Kimberly StricklandCharlotte$1.1M
- Obiageli OgbataCharlotte$861K
- Daniel CarrizosaCharlotte$827K
- Mohamed SalemCharlotte$658K
- Ashley SumrallCharlotte$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.